OpenEvidence
OP
OpenEvidence provides clinical evidence search software for healthcare professionals. Users ask questions and get summarized answers backed by citations to published medical studies and guidelines. The product supports literature review and clinical practice.
Founded by Daniel Nadler (Founder), Zachary Ziegler (Co-founder & CTO)
Blended valuation$14B$12.9B secondary
Valuation history
Weekly blended valuation with priced funding rounds marked on the timeline.
$16.2B
blended valuationfunding round
Jul 25, 2022$0Oct 5, 2026
All rounds
10 funding rounds, newest first.
| Round | Announced | Raised | Post-money |
|---|---|---|---|
| Series E | Sep 24, 2026 | $250M | $15B |
| Series D | Jan 21, 2026 | $250M | $12B |
| Series C | Oct 20, 2025 | $200M | $6B |
| Series B | Jul 15, 2025 | $210M | $3.5B |
| Series A | Feb 19, 2025 | $75M | $1B |
Join Legion to view all 10 rounds.Sign in to Legion
Investors
27 investors across all rounds.
- SCSequoia Capital
- BCBreyer Capital
- GVGoogle Ventures
- DGDST Global
- AHAndreessen Horowitz
- TCThrive Capital
- COCoatue
- COConviction
- CVCraft Ventures
- GRGreycroft
Only Legion members can view the full investor roster. Sign in to Legion
Secondary market activity
Recent buy and sell interest for OpenEvidence shares on the secondary market.
| Kind | Implied valuation | Price / share | Date |
|---|---|---|---|
| $12.5B | — | Oct 6, 2026 | |
| $13.6B | $550.73 | Sep 23, 2026 | |
| $13.6B | $550.73 | Sep 22, 2026 |
Invest in the private markets on Legion
Registered users see full trading activity, every investor, rankings, and live deals.
Data as of Oct 15, 2026. Valuations are estimates blended from primary and secondary-market signals — not investment advice.